BOSTON, Jan. 15 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company's Breast Endoscopy System, the MammoView™, will be featured in a full-page advertisement in the February issue of General Surgery News. The publication, founded in 1972, is circulated to nearly 40,000 general and specialist surgeons each month throughout the United States.
General Surgery News is designed to keep general surgeons informed of the latest developments in the field. The publication features extensive meeting coverage, analysis of journal articles, educational reviews, and information on new drugs and products. General Surgery News' editorial focuses on such topics as prevention and management of health care, associated infections, breast cancer, surgical techniques, and endoluminal therapies.
"Solos Endoscopy is pleased to have its MammoView's™ instrument line displayed in one of the surgical industry's top magazines. The advertisement is the first in a year-long advertising campaign geared towards increasing the exposure of our entire Solos Endoscopy instrument line to potential customers and partners," stated Bob Segersten, President of Solos Endoscopy, Inc.
The advertisement will be available for preview on or before January 22, 2010 at www.solosendoscopy.com.
For more information on General Surgery News, please visit: www.generalsurgerynews.com
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.
Advertisement
General Surgery News is designed to keep general surgeons informed of the latest developments in the field. The publication features extensive meeting coverage, analysis of journal articles, educational reviews, and information on new drugs and products. General Surgery News' editorial focuses on such topics as prevention and management of health care, associated infections, breast cancer, surgical techniques, and endoluminal therapies.
Advertisement
"Solos Endoscopy is pleased to have its MammoView's™ instrument line displayed in one of the surgical industry's top magazines. The advertisement is the first in a year-long advertising campaign geared towards increasing the exposure of our entire Solos Endoscopy instrument line to potential customers and partners," stated Bob Segersten, President of Solos Endoscopy, Inc.
The advertisement will be available for preview on or before January 22, 2010 at www.solosendoscopy.com.
For more information on General Surgery News, please visit: www.generalsurgerynews.com
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.
